{"filing":{"accession_number":"0001628280-26-054264","cik":"0001826667","ticker":"TLSIW","company_name":"TriSalus Life Sciences, Inc.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"tlsi-20260806.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1826667/000162828026054264/tlsi-20260806.htm"},"events":[{"id":25881,"run_id":23498,"accession_number":"0001628280-26-054264","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"TriSalus issued a press release on August 6, 2026 announcing financial results for Q2 2026 ended June 30, 2026, disclosing revenue of $11.4 million, gross margins of 86.8%, operating losses of $9.8 million, and net loss of $9.2 million, along with full-year 2026 revenue guidance of $54–57 million. This is a standard quarterly earnings release disclosure under Item 2.02, material to investors assessing the company's financial performance and operational trajectory.","company_name":"TriSalus Life Sciences, Inc.","ticker":"TLSIW","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26815,"accession_number":"0001628280-26-054264","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"TriSalus issued a press release on August 6, 2026 announcing financial results for Q2 2026 ended June 30, 2026, disclosing revenue of $11.4 million, gross margins of 86.8%, operating losses of $9.8 million, and net loss of $9.2 million, along with full-year 2026 revenue guidance of $54–57 million. This is a standard quarterly earnings release disclosure under Item 2.02, material to investors assessing the company's financial performance and operational trajectory.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:40:42.840698+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26815,"accession_number":"0001628280-26-054264","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"TriSalus issued a press release on August 6, 2026 announcing financial results for Q2 2026 ended June 30, 2026, disclosing revenue of $11.4 million, gross margins of 86.8%, operating losses of $9.8 million, and net loss of $9.2 million, along with full-year 2026 revenue guidance of $54–57 million. This is a standard quarterly earnings release disclosure under Item 2.02, material to investors assessing the company's financial performance and operational trajectory.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:40:42.840698+00:00","company_name":"TriSalus Life Sciences, Inc.","ticker":"TLSIW","filing_date":"2026-08-06"}]}